Hemoglobin A1c level is a prognostic factor for locoregional recurrence in stage III non-small cell lung cancer patients treated with radiotherapy.
Moonkyoo KongYu Jin LimPublished in: Thoracic cancer (2021)
Pretreatment HbA1c level is a significant prognostic factor for locoregional recurrence-free survival in patients with stage III non-small cell lung cancer treated with radical radiotherapy. Routine monitoring of pretreatment HbA1c levels and aggressive glycemic control may be considered to prevent the development of locoregional recurrence in these patients.
Keyphrases
- prognostic factors
- free survival
- glycemic control
- early stage
- type diabetes
- locally advanced
- radiation therapy
- end stage renal disease
- radiation induced
- chronic kidney disease
- blood glucose
- clinical practice
- squamous cell carcinoma
- weight loss
- insulin resistance
- peritoneal dialysis
- adipose tissue
- patient reported outcomes